Skip to main
GBIO
GBIO logo

Generation Bio (GBIO) Stock Forecast & Price Target

Generation Bio (GBIO) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Generation Bio Co. is making substantial progress in its collaboration with Moderna, leveraging insights from this partnership to enhance its own gene therapy platforms focused on T-cell mediated autoimmune diseases, which mitigates risks associated with target selection. The company's initial data demonstrates a promising capability of its ctLNP technology, achieving approximately 98% knockdown of the B2M protein in human T cells, indicating strong therapeutic potential and the efficacy of its platforms. Overall, the positive advancements in Generation Bio's siRNA/ctLNP technology and focused approach towards validated targets position the company favorably within the competitive landscape of gene therapy, suggesting potential value creation for shareholders.

Bears say

Generation Bio Co faces significant challenges that contribute to a negative outlook on its stock. The company may encounter difficulties in securing sufficient capital for the development of its platform technologies, and the timelines for preclinical work and subsequent clinical trials could be extended, heightening the potential for failure in demonstrating efficacy and safety. Additionally, the current challenging financing environment within the biotechnology sector further exacerbates uncertainties surrounding the company’s ability to progress with its gene therapy initiatives, as reflected by its trading below cash position, indicating investor skepticism regarding future prospects.

Generation Bio (GBIO) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Generation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Generation Bio (GBIO) Forecast

Analysts have given Generation Bio (GBIO) a Buy based on their latest research and market trends.

According to 7 analysts, Generation Bio (GBIO) has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Generation Bio (GBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.